AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12667121
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (160 mg/day)
Trial: 12667121
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin and warfarin
Trial: 10941621
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (300 mg) with kinnow juice (300 ml)
Trial: 10941621
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (300 mg) with water (300 ml)
Trial: 7886617
Drug: High transfusion
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High transfusion rates with subcutaneous desferrioxamine injections (Group A)
Trial: 7886617
Drug: Maintaining pretransfusion
RxNorm normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintaining pretransfusion Hb levels between 6-7 g/dl (Group C)
Trial: 3522813
Drug: sorbinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorbinil (100 mg daily for 4 weeks)
Trial: 31410338
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (10 gm two hours before radiotherapy, five days a week during the seven-week course)
Trial: 31410338
Drug: Concurrent chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo-radiotherapy with oral glutamine
Trial: 26324049
Drug: Post-PCI Bivalirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-PCI Bivalirudin infusion
Trial: 26324049
Drug: No post-PCI
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No post-PCI infusion
Trial: 11116284
Drug: LJP-394, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJP-394, 100 mg intravenously weekly
Trial: 3501751
Drug: Ofloxacin 100mg
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin 100mg single dose
Trial: 26369563
Drug: Tiotropium Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat® 5 μg
Trial: 25458454
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution coloading (GroupC)
Trial: 20462055
Drug: Modified Shegan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Shegan Mahuang Decoction (SGMH), one dose per day for 4 weeks
Trial: 20462055
Drug: Montelukast, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, once a day for 4 weeks (4 mg for ages 2-5, 5 mg for ages 6-14)
Trial: 12426013
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg IV
Trial: 12426013
Drug: Meperidine 50
RxNorm normalized name: meperidine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 50 mg IV
Trial: 10598706
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) of the globus pallidus internus (GPi) with L-dopa
Trial: 10598706
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) with L-dopa
Trial: 1936074
Drug: Moxonidine tablets
DrugBank: Moxonidine (DB09242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine tablets (treatment A)
Trial: 1936074
Drug: Intravenous moxonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous moxonidine solution (treatment B)
Trial: 6152884
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of beta-receptor blockade
Trial: 6152884
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of beta-receptor blockade
Trial: 30887470
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SoC) chemotherapy
Trial: 29506504
Drug: Glycopyrronium MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium MDI 28.8 μg
Trial: 29506504
Drug: Glycopyrronium MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium MDI 14.4 μg
Trial: 29506504
Drug: Glycopyrronium MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium MDI 7.2 μg
Trial: 29695902
Drug: Glycopyrronium MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium MDI (all doses)
Trial: 25943172
Drug: Topical bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical bevacizumab 5 mg/mL
Trial: 25943172
Drug: Topical bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical bevacizumab 10 mg/mL
Trial: 22344744
Drug: Tandospirone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone (20 mg)
Trial: 22344744
Drug: Paroxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10 mg)
Trial: 19865833
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (4 sessions)
Trial: 19865833
Drug: Supportive-experiential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-experiential group therapy (4 sessions)
Trial: 19865833
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (Control group, n = 91)
Trial: 1850339
Drug: Atropine (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (i.v. administration)
Trial: 6991446
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg digoxin
Trial: 6991446
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg digoxin over four days
Trial: 31241381
Drug: Multi-variable analysis
RxNorm normalized name: methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multi-variable analysis including doses to the oral cavity, tobacco status, and use of xerogenic medication
Trial: 31241381
Drug: Dose-volume histogram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-volume histogram (DVH) analysis and principal component analysis (PCA)
Trial: 24989855
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg administered intra-operatively, and at 4 and 8 weeks after surgery
Trial: 17761570
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation medication use
Trial: 15475437
Drug: Budesonide (Pulmicort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (Pulmicort Turbuhaler) 800 microg twice daily inhalation for 6 months
Trial: 15973519
Drug: Gln‐PN (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gln‐PN (0.5 g/kg per day; n=15)
Trial: 10442372
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen 20 mg/day for 2 years (group A)
Trial: 10442372
Drug: Oral UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UFT 400 mg/day plus tamoxifen 20 mg/day (group B)
Trial: 8755848
Drug: Pheochromocytoma patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pheochromocytoma patients after pharmacological treatment
Trial: 8755848
Drug: Pheochromocytoma patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pheochromocytoma patients before any treatment
Trial: 1914554
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine delivery system (TTS-1, 0.1 mg/day)
Trial: 6351231
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol (50 micrograms/puff) one puff per nostril X 4 (daily dose 400 micrograms)
Trial: 6351231
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol two puffs per nostril X 2 (daily dose 400 micrograms)
Trial: 6351231
Drug: NPEF and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPEF and use of antihistamine tablets
Trial: 24417602
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition writing about daily activities
Trial: 22958476
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) (Flebogamma®, 2 g/kg)
Trial: 22958476
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previous therapy)
Trial: 9682118
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection of unpreserved lidocaine (0.5 cc of a 1% unpreserved solution)
Trial: 8018617
Drug: Intramyometrial vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramyometrial vasopressin (20 units diluted to 20 ml in normal saline)
Trial: 29976228
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment with artemether-lumefantrine (ISTp-AL)
Trial: 26221889
Drug: Embolization +
RxNorm normalized name: HOSE ANTI-EMBOLISM CALF LEN LARGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embolization + mecobalamin treatment
Trial: 26221889
Drug: Embolization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embolization treatment
Trial: 24215148
Drug: Compassion focused
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compassion focused therapy (CFT) plus treatment as usual (TAU)
Trial: 24215148
Drug: Compassion focused
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compassion focused therapy (CFT)
Trial: 21136070
Drug: Rectal acetaminophen
RxNorm normalized name: acetaminophen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetaminophen (30 mg/kg)
Trial: 21136070
Drug: Peritonsillar bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonsillar bupivacaine infiltration (1 mg/kg)
Trial: 10693094
Drug: Ibuprofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (10 mg/kg loading dose followed by 5 mg/kg every 12 hours)
Trial: 29721510
Drug: Standard pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacotherapy alone (≥21 patients)
Trial: 20940522
Drug: Naftopidil 50mg
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 50mg once daily (Naf group)
Trial: 20940522
Drug: Tamsulosin 0.2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2mg once daily (Tam group)
Trial: 15823909
Drug: UVB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB treatment guided by skin reflectance measurements
Trial: 15823909
Drug: Conventional UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional UVB regimen with fixed dosage increments
Trial: 11978674
Drug: Sulfonylurea, Metformin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea, Metformin, or Insulin
Trial: 7574132
Drug: Nebulized dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized dexamethasone (1.5 mg/kg)
Trial: 2150736
Drug: Aspirin (300-1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300-1500 mg daily)
Trial: 12324552
Drug: Aspirin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (160 mg daily)
Trial: 2150736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin with streptokinase
Trial: 2150736
Drug: Aspirin in
RxNorm normalized name: Non-Aspirin Infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin in healthy doctors (primary prevention trials)
Trial: 29525822
Drug: Clopidogrel (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300-600 mg loading dose, 75 mg daily thereafter)
Trial: 27093052
Drug: Joint reminiscence
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint reminiscence groups (weekly for twelve weeks; monthly maintenance sessions for further seven months)
Trial: 24091061
Drug: Mailed intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mailed intervention providing instructions for taste exposure (14 daily tastes of a disliked vegetable with a sticker reward)
Trial: 21822913
Drug: Casopitant 90
RxNorm normalized name: casopitant
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casopitant 90 mg IV added to ondansetron 8 mg bid oral and dexamethasone 8 mg IV
Trial: 21822913
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to ondansetron 8 mg bid oral and dexamethasone 8 mg IV
Trial: 21822913
Drug: Casopitant 90
RxNorm normalized name: casopitant
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casopitant 90 mg IV
Trial: 18182866
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior program applied twice a week for 50 minutes per session over six weeks
Trial: 16235461
Drug: True ES
RxNorm normalized name: ALCOHOL 36.58 mL in 59 mL TOPICAL GEL [TRUE ESSENTIALS LEMONGRASS HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True ES (electrical stimulation) of ST36 and ST38 acupoints with nitroglycerin infusion
Trial: 16235461
Drug: Sham ES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ES of ST36 and ST38 acupoints with nitroglycerin infusion
Trial: 12198061
Drug: ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.1% 8 mL plus 75 microg of clonidine (Group 1)
Trial: 12198061
Drug: ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.2% 8 mL plus 75 microg of clonidine (Group 3)
Trial: 12198061
Drug: ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.2% 8 mL plus 0.5 mL of NaCl 0.9% (Group 2)
Trial: 10450266
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol before the second speech
Trial: 8666102
Drug: Beta 2-agonist
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2-agonist
Trial: 2135708
Drug: Propentofylline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propentofylline (3 x 300 mg)
Trial: 2135708
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 x 1 tablet)
Trial: 27627654
Drug: AmBisome +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome + SSG (10 mg/kg single dose AmBisome plus 10 days of SSG at 20 mg/kg/day)
Trial: 27627654
Drug: AmBisome +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome + Miltefosine (10 mg/kg single dose AmBisome plus 10 days of miltefosine at 2.5 mg/kg/day)
Trial: 27627654
Drug: Miltefosine alone
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine alone (2.5 mg/kg/day for 28 days)
Trial: 22119570
Drug: Postoperative doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative doxycycline treatment
Trial: 10783345
Drug: recombinant follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle stimulating hormone (rFSH; follitropin alpha)
Trial: 8938163
Drug: IFN-alpha2a (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2a (6 million units starting dose, titrated for 12 months)
Trial: 8938163
Drug: IFN-alphaN1 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alphaN1 (6 million units starting dose, titrated for 12 months)
Trial: 1612300
Drug: L-hyoscyamine
RxNorm normalized name: l-hyoscyamine
DrugBank: Hyoscyamine (DB00424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-hyoscyamine
Trial: 6428279
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg p.o. q 12 h
Trial: 15654172
Drug: Paroxetine 10
RxNorm normalized name: PARoxetine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 10 mg/day and psychotherapy for 8 weeks
Trial: 12208593
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg q.d. (n=70)
Trial: 12208593
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg b.i.d. (n=71)
Trial: 1820897
Drug: Sulphasalazine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine treatment
Trial: 1901686
Drug: Amoxycillin/clavulanate suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate suspension (Spektramox) for 7 days
Trial: 1901686
Drug: Amoxycillin suspension
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin suspension (Imacillin) for 10 days
Trial: 31829245
Drug: Topical‐TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical‐TXA
Trial: 25041227
Drug: Low-exposure everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low-exposure everolimus (3–6 ng/mL) with reduced-exposure cyclosporine (n=56)
Trial: 22299599
Drug: Ethinylestradiol/levonorgestrel combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol/levonorgestrel combined oral contraceptive (20 µg ethinylestradiol/100 µg levonorgestrel) for 21 days
Trial: 10751841
Drug: Topical acne
RxNorm normalized name: SalAc 2% Topical Acne Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acne treatments
Trial: 7096960
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin sulfate 2 g/day for 4 weeks
Trial: 27038920
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone 100 mg every 8 hours for 7 days or until shock reversal
Trial: 27038920
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone 100 mg in patients with baseline cortisol < 15 ug/dL
Trial: 25712437
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical tacrolimus (Tcr)
Trial: 17891547
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus music imagery (twice weekly for up to eight sessions)
Trial: 16173852
Drug: Cognitive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive group therapy (CT)
Trial: 16173852
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (including continuation of pharmacotherapy)
Trial: 12502654
Drug: Community-based nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based nutrition and exercise intervention (11 weekly nutrition classes, triweekly walking groups)
Trial: 15522899
Drug: Sodium ferric
RxNorm normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferric gluconate 125 mg infused over 1 h
Trial: 15522899
Drug: Sodium ferric
RxNorm normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferric gluconate 250 mg infused over 2 h
Trial: 15522899
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) pre-treatment